Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 7/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1593047 | 0.89 | HIF1A (0.65) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593340 | 0.84 | HIF1A (0.75) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593540 | 0.82 | HIF1A (0.74) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593598 | 0.82 | HIF1A (0.92) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1593685 | 0.82 | HIF1A (0.70) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL17451661 | 0.79 | HIF1A (0.59) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610454 | 0.78 | HIF1A (0.58) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL12610265 | 0.78 | HIF1A (1.00) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL4522145 | 0.78 | HIF1A (0.75) | HIF1AALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL4527044 | 0.76 | HIF1A (0.72) | HIF1AALDH1A1SMN1; SMN2LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8575143-B2 | 3-aryl-substituted quinazolones, and uses thereof | PROLEXYS PHARMACEUTICALS, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | Prolexys Pharmaceuticals ,Inc. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092489-A1 | 3-Aryl-Substituted Quinazolones, and Uses Thereof | MKI67, MCL1, HCCS | HIF1A 1381/4885ALDH1A1 365/4885SMN1; SMN2 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.